Eli Lilly Files 8-K on Debt Issuances

TL;DR

LLY dropped an 8-K detailing new debt issuances, including $1.625B due 2026 and $1.125B due 2051.

AI Summary

Eli Lilly and Company (LLY) filed an 8-K on August 14, 2024, reporting on other events and financial statements. The filing details various debt issuances, including $1.625 billion in notes due June 2, 2026, and $1.125 billion in notes due 2051. These issuances are part of the company's ongoing financing activities.

Why It Matters

This filing indicates Eli Lilly is actively managing its capital structure through significant debt offerings, which could impact its financial leverage and future investment capacity.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of debt issuance and does not indicate any unusual or negative events for the company.

Key Numbers

• $1.625B — Notes Due June 2, 2026 (Debt issuance)
• $1.125B — Notes Due 2051 (Debt issuance)

Key Players & Entities

• Eli Lilly & Co (company) — Filer
• LLY (company) — Ticker Symbol
• $1.625 billion (dollar_amount) — Notes due June 2, 2026
• $1.125 billion (dollar_amount) — Notes due 2051

FAQ

Key Financial Figures

• $750,000,000 — the issuance and sale by the Company of $750,000,000 aggregate principal amount of its 4.150
• $1,000,000,000 — 150% Notes due 2027 (the "2027 Notes"), $1,000,000,000 aggregate principal amount of its 4.200
• $1,250,000,000 — 200% Notes due 2029 (the "2029 Notes"), $1,250,000,000 aggregate principal amount of its 4.600
• $4.96 billion — Company, net proceeds of approximately $4.96 billion. Upon the occurrence of an Event of D

Filing Documents

• d876011d8k.htm (8-K) — 50KB
• d876011dex11.htm (EX-1.1) — 256KB
• d876011dex43.htm (EX-4.3) — 184KB
• d876011dex51.htm (EX-5.1) — 14KB
• d876011dex52.htm (EX-5.2) — 11KB
• g876011dsp06.jpg (GRAPHIC) — 4KB
• g876011dsp07.jpg (GRAPHIC) — 2KB
• g876011dsp09.jpg (GRAPHIC) — 2KB
• g876011g0813114520716.jpg (GRAPHIC) — 3KB
• 0001193125-24-200435.txt ( ) — 847KB
• lly-20240812.xsd (EX-101.SCH) — 6KB
• lly-20240812_def.xml (EX-101.DEF) — 16KB
• lly-20240812_lab.xml (EX-101.LAB) — 28KB
• lly-20240812_pre.xml (EX-101.PRE) — 18KB
• d876011d8k_htm.xml (XML) — 16KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 1.1 Underwriting Agreement, dated August 12, 2024, among Eli Lilly and Company and BNP Paribas Securities Corp., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein. 4.1* Indenture, dated February 1, 1991, among Eli Lilly and Company and Deutsche Bank Trust Company Americas, as successor to Citibank, N.A., as Trustee. 4.2 Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed above. 4.3 Form of Officers' Certificate setting forth the terms and form of the Notes. 4.4 Form of 4.150% Note due 2027 (included in Exhibit 4.3 above). 4.5 Form of 4.200% Note due 2029 (included in Exhibit 4.3 above). 4.6 Form of 4.600% Note due 2034 (included in Exhibit 4.3 above). 4.7 Form of 5.050% Note due 2054 (included in Exhibit 4.3 above). 4.8 Form of 5.200% Note due 2064 (included in Exhibit 4.3 above). 5.1 Opinion of Kirkland & Ellis LLP. 5.2 Opinion of Jonathan Groff, Esq. 23.1 Consent of Kirkland & Ellis LLP (included as part of Exhibit 5.1). 23.2 Consent of Jonathan Groff, Esq. (included as part of Exhibit 5.2). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Incorporated by reference to the same-numbered exhibit of the Company's Registration Statement on Form S-3 (File No. 333-186979), filed with the Securities and Exchange Commission ("SEC") on March 1, 2013. Incorporated by reference to the same-numbered exhibit of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 (File No. 001-06351), filed with the SEC on February 27, 2009.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Michael Thompson Name: Michael Thompson Title: Associate Vice President Finance, Assistant Treasurer Dated: August 14, 2024

View Full Filing

View this 8-K filing on SEC EDGAR